Delving into the Latest Updates on Technische Universität Braunschweig with Synapse

Overview

Tags

Immune System Diseases

Infectious Diseases

Nervous System Diseases

Small molecule drug

Fc fusion protein

CAR-T

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	4
Infectious Diseases	3
Nervous System Diseases	2
Neoplasms	2

Top 5 Drug Type	Count

Small molecule drug	3
Fc fusion protein	2
CAR-T	2

Top 5 Target	Count

NMDA receptor(Glutamate [NMDA] receptor)	2
phzB(Phenazine biosynthesis enzyme)	1
CD39L3(ectonucleoside triphosphate diphosphohydrolase 3)	1
DGCR2(DiGeorge syndrome critical region gene 2)	1

This study presents a comprehensive spectroscopic investigation of two nitric oxide (NO) absorption transitions (R11.5 Ω1/2 at 1914.99 cm^-1 and R11.5 Ω3/2 at 1915.76 cm^-1) using laser absorption spectroscopy. By employing two complementary experimental systems, namely a continuous flow gas cell for line intensity measurements and a shock tube facility for temperature dependence coefficient characterization, we attained exceptional measurement accuracy with line intensity uncertainties as low as 0.95 % while extending the accessible temperature range to 1742 K. The study systematically characterizes temperature dependence of pressure broadening coefficients in four buffer gases (Ar, N₂, He, CO₂), revealing distinct gas-specific behaviors, particularly the weak interaction between NO and helium. A rigorous metrological analysis demonstrated substantial improvements in NO quantification accuracy, achieving 12.4-fold and 3.5-fold uncertainty reductions for scanned-wavelength and fixed-wavelength LAS, respectively. The development of uncertainty mapping and dynamic uncertainty evaluation methodologies further enhanced measurement reliability under transient conditions. The comprehensive dataset and methodological innovations presented in this work address critical gaps in high temperature NO spectroscopy and enable more accurate molecular diagnostics in energy, environmental, and industrial applications.

01 Feb 2026·BIORESOURCE TECHNOLOGY

Evaluation of anaerobic sludge digestion in combination with thermal alkaline process as pre- and post-treatment: Impacts on energy, economic, and CO2 footprint balances

Article

Author: Xu, Xiao ; Dockhorn, Thomas

To determine whether wastewater treatment plants (WWTPs) should use the thermal hydrolysis process (THP) or the thermal alkaline process (TAP) as sludge pretreatment or posttreatment methods, this study was conducted on five WWTPs implementing THP/TAP under seven different scenarios. The evaluation focused on impacts on energy, economic, and CO_2eq. balances compared to conventional anaerobic sludge digestion. In this study, THP/TAP as a posttreatment method yielded better results in energy, economic, and CO_2eq. balances than pretreatment. TAP of digested sludge (DS) at pH 9 achieved the highest net electricity generation of 344.7-472.3 kWh/t total solids (TS). An economic profit of 29.9-171-3 US$/tTS can be obtained from digesting the liquid fraction of THP-treated DS, and in this scenario, CO_2eq. emissions can be further reduced by 149.8 ± 42 kg/tTS. However, additional space is required for the construction of a digester or an upflow anaerobic sludge blanket in the DS posttreatment.

01 Feb 2026·JOURNAL OF MEDICAL ETHICS

Large language models for surgical informed consent: an ethical perspective on simulated empathy

Article

Author: Kacprowski, Tim ; Salloch, Sabine ; Ursin, Frank ; Balke, Wolf-Tilo ; Rudra, Pranab

Informed consent in surgical settings requires not only the accurate communication of medical information but also the establishment of trust through empathic engagement. The use of large language models (LLMs) offers a novel opportunity to enhance the informed consent process by combining advanced information retrieval capabilities with simulated emotional responsiveness. However, the ethical implications of simulated empathy raise concerns about patient autonomy, trust and transparency. This paper examines the challenges of surgical informed consent, the potential benefits and limitations of digital tools such as LLMs and the ethical implications of simulated empathy. We distinguish between active empathy, which carries the risk of creating a misleading illusion of emotional connection and passive empathy, which focuses on recognising and signalling patient distress cues, such as fear or uncertainty, rather than attempting to simulate genuine empathy. We argue that LLMs should be limited to the latter, recognising and signalling patient distress cues and alerting healthcare providers to patient anxiety. This approach preserves the authenticity of human empathy while leveraging the analytical strengths of LLMs to assist surgeons in addressing patient concerns. This paper highlights how LLMs can ethically enhance the informed consent process without undermining the relational integrity essential to patient-centred care. By maintaining transparency and respecting the irreplaceable role of human empathy, LLMs can serve as valuable tools to support, rather than replace, the relational trust essential to informed consent.

1

News (Medical) associated with Technische Universität Braunschweig

15 Jun 2022

·www.biospace.com

Ymmunobio Signs Collaboration Agreement with YUMAB

RIEHEN, SWITZERLAND, June 14, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM (carcinoembryonic antigen-related cell adhesion molecules) antibodies as anti-cancer treatments, today announced that it has signed a collaboration agreement with YUMAB GmbH, a privately-held German biotechnology company. YUMAB provides technologies and contract research for the development of fully human antibodies for all therapeutic fields. Within the scope of the collaboration, Ymmunobio AG will complement its antibody development by utilizing YUMAB’s expertise and platform for optimizing its antibodies. “We look forward to our collaboration being a productive complement to our capabilities,” said Dr. Katrin Rupalla, CEO, Ymmunobio AG. “Ymmunobio shares a commitment with YUMAB to accelerate drug development through antibody optimization.” “We’re excited by the prospect of working with Ymmunobio to facilitate new pathways to antibody development,” said Dr. Thomas Schirrmann, YUMAB founder and CEO. “Ymmunobio shares our vision to accelerate drug discovery and ultimately improve patient outcomes.” Ymmunobio is developing a proprietary class of CEACAM1 immune agonistic antibodies in order to employ the immune system to fight cancer. Financial conditions of the agreement were not disclosed. ABOUT YMMUNOBIO Ymmunobio AG, a preclinical stage oncology biotech company, was founded by Dr. Katrin Rupalla and is committed to developing a proprietary class of CEACAM antibodies to increase the efficiency of the adaptive and innate immune system to fight cancer. Ymmunobio’s research targets defined CEACAM receptor isoforms that play a major role in the immune response and cancer cell evolution. The company’s proprietary platform is based on the leading research of Dr. Bernhard B. Singer, University Essen/Duisburg, Germany. ABOUT YUMAB YUMAB GmbH, a leading provider of contract research, technologies, and R&D services for the development of fully human, therapeutic antibodies, was founded in 2012 by scientists of the University of Braunschweig. A global player in human monoclonal antibody development, YUMAB is focused on the use of fully human antibodies for immunotherapies. For more information, please visit . Contact: Dr. Katrin Rupalla, info@ymmuno.bio

CollaborateAntibody

100 Deals associated with Technische Universität Braunschweig

Login to view more data

100 Translational Medicine associated with Technische Universität Braunschweig

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

5

Preclinical

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Compound 20c(Technische Universität Braunschweig) ( phzB )	Pseudomonas aeruginosa infection More	Preclinical
GluN1-GluN2A-Fc (YUMAB) ( NMDA receptor )	Anti-N-Methyl-D-Aspartate Receptor Encephalitis More	Preclinical
PF-1140	Mycoses More	Preclinical
GluN1-GluN2B-Fc (Yumab) ( NMDA receptor )	Anti-N-Methyl-D-Aspartate Receptor Encephalitis More	Preclinical
Arcopilins A	Staphylococcus Aureus Infections More	Preclinical